1
Clinical Trials associated with Dendritic cell-gp100-MART-1 antigen vaccine(Genzyme) / Unknown statusPhase 1/2 Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells combined with melanoma antigens may make the body build an immune response to tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for stage III or stage IV melanoma.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have stage III or stage IV melanoma that cannot be surgically removed.
100 Clinical Results associated with Dendritic cell-gp100-MART-1 antigen vaccine(Genzyme)
100 Translational Medicine associated with Dendritic cell-gp100-MART-1 antigen vaccine(Genzyme)
100 Patents (Medical) associated with Dendritic cell-gp100-MART-1 antigen vaccine(Genzyme)
100 Deals associated with Dendritic cell-gp100-MART-1 antigen vaccine(Genzyme)